Clinical Trial Detail

NCT ID NCT04149574
Title A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

non-invasive bladder urothelial carcinoma

transitional cell carcinoma

Therapies

BCG solution + Nivolumab

BCG solution

Age Groups: senior adult

No variant requirements are available.